⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17680188 | 0.87 | — | — | |
| SCHEMBL17680182 | 0.79 | — | — | |
| SCHEMBL13177938 | 0.78 | — | — | |
| SCHEMBL16256353 | 0.78 | HIF1A (0.30) | — | |
| SCHEMBL4953851 | 0.76 | PTPN1 (0.31) | — | |
| SCHEMBL736990 | 0.76 | LMNA (0.44) | — | |
| SCHEMBL6882235 | 0.76 | LMNA (0.44) | — | |
| SCHEMBL16796012 | 0.76 | LMNA (0.44) | — | |
| SCHEMBL5933973 | 0.76 | LMNA (0.44) | — | |
| SCHEMBL3851126 | 0.76 | LMNA (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015055497-A1 | SUBSTITUTED PESTICIDAL PYRAZOLE COMPOUNDS | BASF SE (DE) | 2015-04-23 | — | — | WO | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8067379-B2 | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-7759499-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759499-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2010-07-20 | — | — | US | disclosed |
| US-7718691-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2010-05-18 | — | — | US | disclosed |
| US-7635694-B2 | For treating hepatitis C and related disorders such as HIV, AIDS (Acquired Immune Deficiency Syndrome) | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| US-7619094-B2 | Ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | SCHERING CORPORATION (US) | 2009-11-17 | — | — | US | disclosed |
| US-7550559-B2 | Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550559-B2 | Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7192957-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192957-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2007-03-20 | — | — | US | disclosed |
| US-7186747-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186747-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-20070049536-A1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070042968-A1 | Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070032434-A1 | used for the treatment or prevention of HCV or amelioration the symptoms of hepatitis C infection, by modulating the interaction of an HCV polypeptide with HCV proteases | SCHERING CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070032434-A1 | used for the treatment or prevention of HCV or amelioration the symptoms of hepatitis C infection, by modulating the interaction of an HCV polypeptide with HCV proteases | SCHERING CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-7173057-B2 | Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus | SCHERING CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173057-B2 | Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus | SCHERING CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |